Tandem Diabetes Care (TNDM) Asset Writedowns and Impairment (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Asset Writedowns and Impairment for 14 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Asset Writedowns and Impairment rose 51.4% year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2026 stood at $11.3 million (down 25.43% YoY), and the FY2025 full-year result was $9.5 million, down 5.02% from the prior year.
• Asset Writedowns and Impairment climbed to $3.2 million in Q2 2026 per TNDM's latest filing, from $2.1 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $12.7 million in Q2 2023 and bottomed at $846000.0 in Q1 2022.
• Historically, Asset Writedowns and Impairment has averaged $3.1 million across 5 years, with a median of $2.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment surged 1011.28% in 2023, then plunged 88.0% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at $4.6 million in 2022, then tumbled by 71.64% to $1.3 million in 2023, then surged by 104.66% to $2.7 million in 2024, then increased by 2.09% to $2.7 million in 2025, then advanced by 18.88% to $3.2 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $3.2 million, $2.1 million, and $2.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.